Gender Studies

Appearance Policing Produces Self-Surveillance Developmental and sociological research shows that repeated correction related to body and appearance increases self-monitoring and anticipatory compliance. Children learn not only what rules exist, but how to manage themselves to avoid scrutiny (Foucault; contemporary school discipline research). For Black girls, appearance policing is racialized and gendered. Expectations around hair, posture, clothing, and tone intersect with stereotypes that frame Black femininity as excessive, unprofessional, or inappropriate unless carefully controlled (Morris, Pushout; Blake et al.). Over time, Black girls learn to: ▪️ manage their bodies for adult comfort ▪️suppress culturally rooted expression ▪️equate visibility with risk What is often later mischaracterized as insecurity or over-compliance is frequently the result of early training in bodily self-regulation under unequal standards. This is not an individual preference. It is a patterned developmental response. Attribution: Chapter Two of Slay All Day offers age-appropriate language that reinforces bodily autonomy, self-worth, and visibility for Black girls. Who needs to pay attention: Classroom teachers, counselors, SEL teams, and youth program staff who shape daily norms around appearance and “appropriateness.”

Last week I wrote about women, perimenopause, neurodiversity and alcohol use. Someone commented that focusing on women's health was "gender divisive", and I want to sit with that for a moment. Because the field of medicine has spent most of its history studying men almost exclusively, and the idea that addressing that gap is somehow unfair is worth unpacking. Most of what we know about the human body was worked out using men. Not because women's bodies weren't worth studying. Because for a long time, the people doing the studying were men, the people funding the research were men, and the assumption was that male biology was the default and everything else was a variation. Women were routinely excluded from clinical trials well into the 1990s. The reasoning was that hormonal fluctuations would complicate the data. The consequence was that we built an entire evidence base that didn't reflect half the population. We're still working out what that cost us. It shows up in cardiology, where women's heart attacks present differently and get missed. It shows up in pain medicine, where women are more likely to have their symptoms dismissed as psychological. And it shows up in addiction medicine, where the research, the diagnostic tools, and the treatment models were built around a male pattern of use. Women drink differently. They become dependent faster, at lower levels of consumption. They experience more severe health consequences earlier. And they often come to alcohol through a completely different door, stress, trauma, undiagnosed neurodiversity, hormonal shifts that nobody connected to anything. But the system they walk into was built for someone else. Medicine is changing. The gender shift in the medical workforce is real and long overdue. More women in clinical leadership means more of these questions get asked, more of these patterns get noticed, and more of this research gets done. But we're still catching up on decades of absence. And until we're honest about that, we'll keep being surprised by presentations that shouldn't surprise us at all. #WomensHealth #MedicalResearch #AddictionMedicine #GenderEquity #CleanSlateClinic #RewriteTheStory

WHOOP just launched a Women's Health Specialized Blood Biomarker Panel. 11 female-specific biomarkers. From hormonal transitions to thyroid function to bone health. This is not just a product update. This is a signal like we have quite some others by OURA and other health tech companies happily. Because women's health has been systematically neglected for decades. And the data is brutal. Here are some facts: → Only 5% of global R&D funding goes to women's health. Of that, 4% is for cancers. Just 1% covers everything else. A quarter of that 1% is limited to fertility research alone. → Fewer than 30% of participants in early-phase clinical trials are women. The FDA banned women of childbearing age from trials in 1977. The ban was lifted in 1993. The bias never left. → Cardiovascular disease is the number one killer of women. Yet only one-third of cardiac trial patients are female. And only 4% of the NIH's coronary artery disease budget funds women-focused research. → 80% of autoimmune disease cases occur in women. For decades, the standard treatment for frozen shoulder, which disproportionately affects women, was "just wait two years." → Women live on average five years longer than men. But they spend 25% more of their lives in poor health or with disability. → PMS, menopause, endometriosis, and maternal health conditions make up 14% of women's health burden. They received less than 1% of research funding between 2019 and 2023. The medical system was built on male bodies as the default. Women are not small men. Their biology is different. Their symptoms present differently. Their hormones create entirely different health dynamics. And yet, most health tech still treats everyone the same That is why the WHOOP announcement also matters. Their new panel tests biomarkers that dive into cycle regulation, perimenopause, thyroid function, nutrient sufficiency, and bone-metabolic resilience. Layered on top of continuous wearable data. Correlated with recovery, strain, sleep, and stress patterns over time. WHOOP also published a Menstrual Cycle White Paper and launched Hormonal Symptom Insights and Predictions, a feature that builds a personalized model of each member's cycle. Women represent the fastest-growing segment of WHOOP members. 150% year-over-year growth. And women engage with WHOOP AI 30% more than men. The demand is there. The gap is massive. And finally, companies are starting to close it. But this is bigger than WHOOP. We need to start thinking about health gender-specifically. Not as a niche. Not as a nice-to-have. As the foundation. Closing the women's health gap could unlock up to $1 trillion in annual global GDP by 2040. But more importantly, it would give billions of women the health insights and care they actually deserve. The future of health is not one-size-fits-all. It never should have been. Source: WHOOP, McKinsey Health, World Economic Forum, Nature, NIH, AAMC, Harvard Medicine Magazine Picture: whoop

Sex and gender are widely acknowledged as important variables in #research. This paper shows how inconsistently they are actually studied. A new Nature Neuroscience Perspective by Michelle Roche et al., led by the international #PAINDIFF Network, brings much-needed methodological clarity to this gap. The recommendations are grounded in a global survey of 483 pain researchers, combined with an expert consensus process spanning preclinical, clinical, and translational research. 💡 Several findings motivating the recommendations stood out: • Most researchers report that sex is important, yet far fewer routinely include both sexes in study design • Even when both sexes are included, sex-disaggregated analysis and reporting remain inconsistent • Gender is rarely incorporated beyond basic demographics in human and clinical studies • Common barriers persist, including limited resources, uncertainty about relevance, and lack of clear guidance • In preclinical research, persistent assumptions about increased variability in females continue to shape design choices These gaps matter. Inconsistent inclusion and reporting limit reproducibility, complicate comparison across studies, and reduce translational value. In response, the authors propose a clear, pragmatic framework, including five universal recommendations that should apply to most studies: 1. Include males and females as standard practice, with explicit justification when only one sex is studied 2. Account for sex in randomization, counterbalancing, and testing order 3. Power studies to detect sex differences when sex is a primary variable or when prior evidence suggests sex-specific effects 4. Report experimental design in sufficient detail to support replication and pooled analyses 5. Analyze and report data disaggregated by sex, regardless of whether differences are statistically significant Additional recommendations address preclinical specifics, such as reporting the sex of cell lines and environmental conditions, and human research considerations, including how sex assigned at birth and gender identity are collected, reported, and ethically handled. Although this Perspective focuses on pain and related research, the challenges it identifies and the solutions it proposes are relevant across therapeutic areas and research domains where variability, rigor, and generalizability matter. At GSD Health Research, much of our work sits at this intersection of study design, real-world complexity, and methodological rigor, particularly when sex- and gender-related variability matters for interpretation and translation. 🔗 Nature Neuroscience (2025): “Recommendations for the inclusion and study of sex and gender in research” https://lnkd.in/dGdzdxpv

People often ask when I “decided” to be transgender, as if it were a lifestyle choice made over breakfast. The reality is that from my earliest memories, I knew something wasn't quite right. Emerging research now tells a biological story that resonates with my experience: being trans isn’t a choice; it’s an innate reality. It Starts Before Birth: One of the most compelling pieces of evidence lies in foetal development. Genital formation occurs in the first trimester, while brain differentiation happens in the second. This means the hormonal environment can influence each process independently. A foetus can develop typical male genitals yet have a brain that formed under different hormonal conditions. Studies on girls with Congenital Adrenal Hyperplasia (CAH) - who are exposed to high prenatal testosterone -consistently show more male-typical behaviour despite their upbringing. This demonstrates that hormones in the womb shape gender identity long before society intervenes. It’s in Our Genes: Genetics provides another piece of the puzzle. In 2024, researchers at the Hudson Institute of Medical Research analysed the DNA of 380 transgender women and found 12 specific gene variants significantly more common than in non-transgender males. These genes are involved in how the body processes sex hormones like estrogen and androgens. Similarly, scientists at the Medical College of Georgia identified 21 variants across 19 genes involved in estrogen signalling that may be linked to gender dysphoria. These findings suggest that some individuals process hormones differently, leading the brain to develop along distinct pathways. Our Brains Tell a Story: Brain imaging adds a structural layer to the narrative. Research published in Nature found that the brains of transgender women show distinct patterns that don't simply match cisgender men or women. A major review by the U.S. National Institutes of Health found consistent differences in brain structure and function between transgender and cisgender people. It’s not as simple as being "trapped in the wrong body"; rather, gender identity emerges from a complex mix of genetics and neurobiology. Why This Matters: Science is rarely definitive. A 2025 review in ScienceDirect described the evidence as “growing” but not yet exhaustive. No single "trans gene" exists because human identity is rarely the result of a single biological switch. Transgender people shouldn’t need scientific proof to justify their existence. My identity is real regardless of research studies: However, for those with genuine curiosity, science offers a vital truth: our experience is consistent, real, and rooted in a biological foundation we are only beginning to fully understand.